Jim Cramer Says Cardinal Health Is “the Stock That Is Made for This Moment”

Nov 20, 2026
jim-cramer-says-cardinal-health-is-“the-stock-that-is-made-for-this-moment”

Chris Lange

5 min read

Quick Read

  • Jim Cramer calls Cardinal Health (CAH) “the stock that is made for this moment,” and shares have already climbed 34% this year.

  • Cardinal beat earnings and revenue estimates, raised guidance, and renewed CVS through 2032, even as CVS supplies 28% of revenue.

  • At 22x forward earnings, much of the rally looks priced in, leaving long-term holders a durable compounder with slower easy gains.

  • Released: The Definitive Guide to Retirement Income. It is a free guide from Fisher Investments covering what your retirement will really cost, where the cash flow should come from, and how much you can safely withdraw each year. Learn more here. Learn More Here › (sponsor)

Jim Cramer used his “Stop Trading” segment on CNBC on November 17, 2026, to spotlight a company most investors rarely think about. “I want to present a stock that is literally the stock that is made for this moment. It’s called Cardinal Health,” he said, calling it “a company that distributes pharmaceuticals and they do some health care manufacturing, pharmaceutical packaging.”

Jim Cramer gesturing emphatically with raised finger while speaking on stage

Tulane Public Relations/Wikimedia Commons

The market has already rewarded Cardinal Health (NYSE:CAH). Shares finished at $272.34 on November 19, up 33.76% year to date. They slipped 2.09% over the past week and sit about 4.9% below the 52-week high of $286.29.

CAH price target

CAH Price Target — 24/7 Wall St.

How a Drug Middleman Earns Steady Profits

Cardinal buys branded, specialty, and generic drugs from manufacturers and delivers them to pharmacies, hospitals, and physician practices. It earns a thin spread on huge volume, collects fees from drugmakers, and pressures generics’ margins through Red Oak Sourcing, a venture it runs with CVS Health (NYSE:CVS). It also makes medical products, runs nuclear pharmacies and sells home-health supplies. With McKesson (NYSE:MCK) and Cencora (NYSE:COR), it serves drugmaker AbbVie (NYSE:ABBV), accounting for substantially all of AbbVie’s U.S. pharmaceutical sales in 2025.

People fill prescriptions in any economy, and that’s the heart of the defensive case. The stock’s beta of 0.521 shows it has historically moved about half as much as the broader market.

——

Now Available: The Definitive Guide to Retirement Income

Many successful investors eventually reach the same moment. The saving is done, the portfolio is built, and the question quietly changes from how much can I grow this to how much can I take out? Get that second question wrong and decades of good investing can come apart in a handful of years.

That is exactly what The Definitive Guide to Retirement Income helps answer. It covers what your retirement could actually cost, which income sources are worth using, and the withdrawal math that decides whether the money lasts. It is free today from Fisher Investments. Read More Here ›

Leave a comment